(Q38217354)

31 August 2017

title

Advances in therapy for pediatric sarcomas (English)

1 reference

31 August 2017

author

Holly Spraker-Perlman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24894064%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Damon R. Reed

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24894064%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Aaron Weiss

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24894064%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Jonathan Gill

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24894064%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

John Goldberg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24894064%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Joanne Lagmay

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24894064%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Rajkumar Venkatramani

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24894064%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

publication date

1 January 2014

1 reference

31 August 2017

published in

Current Oncology Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24894064%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24894064%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24894064%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

395

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24894064%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11912-014-0395-z

6 June 2020

exact match

0 references

cites work

Bone tumors in adolescents and young adults

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

The multidisciplinary management of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Chemotherapy resistance in osteosarcoma: current challenges and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

A review of clinical and molecular prognostic factors in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Using epidemiology and genomics to understand osteosarcoma etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

International collaboration is feasible in trials for rare conditions: the EURAMOS experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Children's Oncology Group's 2013 blueprint for research: bone tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Microtubules as a target for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Second cancers in patients with the Ewing sarcoma family of tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Osteosarcoma lung metastases detection and principles of multimodal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Systematic identification of genomic markers of drug sensitivity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Pathologic femur fractures after limb-sparing treatment of soft-tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Radiation therapy and late mortality from second sarcoma, carcinoma, and hematological malignancies after a solid cancer in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Gardner's syndrome (familial adenomatous polyposis): a cilia-related disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Pediatric aggressive fibromatosis: a retrospective analysis of 13 patients and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Multimodality management of desmoid tumors: how important is a negative surgical margin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Long-term results with radiation therapy for pediatric desmoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Secreted heat shock protein gp96-Ig: an innovative vaccine approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Cytotoxic T-lymphocyte-associated antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, German

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

High-throughput oncogene mutation profiling in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0395-Z

Aggressive intra-abdominal fibromatosis in children and response to chemotherapy

21 January 2018

1 reference

12 December 2020

Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies

1 reference

12 December 2020

Immunotherapy of sarcomas

1 reference

12 December 2020

Nonsurgical management of children with recurrent or unresectable fibromatosis

1 reference

12 December 2020

Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.

1 reference

12 December 2020

Pediatric desmoid tumor: retrospective analysis of 63 cases

1 reference

12 December 2020

Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols

1 reference

12 December 2020

Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group

1 reference

12 December 2020

Desmoid fibromatosis: a clinicopathologic study of 25 children

1 reference

12 December 2020

Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.

1 reference

12 December 2020

Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex

1 reference

12 December 2020

Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma

1 reference

12 December 2020

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.

1 reference

12 December 2020

Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital

1 reference

12 December 2020

Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)

1 reference

12 December 2020

Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group

1 reference

12 December 2020

Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas

1 reference

12 December 2020

Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study

1 reference

12 December 2020

Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor.

1 reference

12 December 2020

Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells.

1 reference

12 December 2020

Adult-Type Soft Tissue Sarcomas in Pediatric-Age Patients: Experience at the Istituto Nazionale Tumori in Milan

1 reference

12 December 2020

Aggressive fibromatosis in children and adolescents: the Italian experience

1 reference

12 December 2020

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

12 December 2020

Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis

1 reference

12 December 2020

Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.

1 reference

12 December 2020

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R

1 reference

12 December 2020

Rhabdomyosarcoma in children: a SEER population based study

1 reference

12 December 2020

Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)

1 reference

12 December 2020

Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma

1 reference

12 December 2020

10.1007/S11912-014-0395-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24894064%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

6 June 2020

1023873605

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24894064%20AND%20SRC:MED&resulttype=core&format=json